CN107119072A - One kind is overexpressed ZEB2 gene plasmids and its construction method and application - Google Patents

One kind is overexpressed ZEB2 gene plasmids and its construction method and application Download PDF

Info

Publication number
CN107119072A
CN107119072A CN201710315809.7A CN201710315809A CN107119072A CN 107119072 A CN107119072 A CN 107119072A CN 201710315809 A CN201710315809 A CN 201710315809A CN 107119072 A CN107119072 A CN 107119072A
Authority
CN
China
Prior art keywords
zeb2
ser
glu
reaction system
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710315809.7A
Other languages
Chinese (zh)
Other versions
CN107119072B (en
Inventor
张磊
徐涛
王啸
潘林鑫
丁琪
汪洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Medical University
Original Assignee
Anhui Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Medical University filed Critical Anhui Medical University
Priority to CN201710315809.7A priority Critical patent/CN107119072B/en
Publication of CN107119072A publication Critical patent/CN107119072A/en
Application granted granted Critical
Publication of CN107119072B publication Critical patent/CN107119072B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Abstract

ZEB2 gene plasmids are overexpressed the invention discloses one kind, are formed by ZEB2 gene C DS sequences and the recombination to construct of pEGFP C2 carrier for expression of eukaryon;Its nucleotides such as sequence table SEQ ID NO:1, positioned at the 134th 3778 of ZEB2 genes;Amino acid sequence such as sequence table SEQ ID NO:Shown in 2.The invention also discloses a kind of construction method of overexpression ZEB2 gene plasmids and application.The advantage of the invention is that:(1) contribute to study ZEB2 gene functions, and useful biology tool is provided to effect of the inflammation in the AKI courses of disease to study it;(2) laid a good foundation for further research ZEB2 function, and AKI gene therapy.

Description

One kind is overexpressed ZEB2 gene plasmids and its construction method and application
Technical field
The present invention relates to technical field of bioengineering, more particularly to a kind of overexpression ZEB2 gene plasmids and its construction method And application.
Background technology
Acute injury of kidney (acute kidney injury, AKI) is one of most common Severe acute disease in clinical departments room, Can be caused by many reasons, about AKI mechanism be always kidney trouble field concern important scientific issues.Recognize at present For AKI is also a kind of disease of inflammatory reaction mediation, but ischemia-reperfusion starts the mechanism of nephridial tissue inflammatory reaction not completely It is clear.Serious anuria AKI is increased to from slight serum creatinine, AKI degree and clinical manifestation are numerous, and AKI dies of illness with patient Rate, the generation of CKD (CKD) and maintenance dialysis rate are closely related.Epidemiological survey data display, the AKI incidences of disease Increase year by year, increase to 2 888 (per million people) of 2009 by 610 (per million people) of 1988, commonly living The AKI incidences of disease are 3%-5% in institute patient, and 30%-50% is more up in ICU;Prognosis simultaneously for AKI and lapse to compared with There is more deep understanding in the past.Therefore, AKI generation, development and the means for finding effective treatment AKI how is prevented and treated It is particularly important with medicine.
Genetic engineering, also known as gene recombination technology, are entering in vitro to DNA of growing up nineteen seventies A special kind of skill of row operation, is widely used in disease basic research, gene therapy, genetic immunization, gene vaccine etc..Its three elements point It is not:Enzyme, target gene, carrier.And carrier for expression of eukaryon is to be used in genetic engineering build the one of eukaryotic gene expression system Carrier is planted, in recent decades, scholars have carried out the correlative studys such as various diseases, gene around carrier for expression of eukaryon, in base It is that medical scientific opens brand-new route because being done a lot of work in terms of engineering.
ZEB2 is called ZFHX1B, SIP1 etc., the E box joint zinc finger proteins (zinc belonged in zinc fingers transcription factor Finger E-box binding homeobox) family member, be required transcription factor in embryonic development, first on ZEB2 report is the mRNA that ZEB2 is found that in the embryo of Africa xenopus.The ZEB2 assignments of genes gene mapping on chromosome 2q22.3, By ZFHX1B coded by said gene, comprising 9 extrons and 8 intrones, CDS areas are 3645bp.ZEB2 is by 1215 amino acid Residue constitute, its molecular weight is about 136KD, comprising 2 zinc finger clusters (zinc finger cluster) and connection the two zinc Refer to the variable sequence of cluster.Each zinc fingers in N-terminal and C-terminal can be in the conditioned zone of independent binding purpose gene 5 '-CACCT sequences.ZEB2 belongs to transcription factor, and initial research is thought to be positioned in core, it has recently been demonstrated that in born of the same parents There is expression in slurry and karyon.It participates in a variety of vital movements such as cell growth, differentiation, apoptosis, embryonic development and inflammatory reaction Regulation and control.
People source ZEB2 genes are registered in GenBank, and number of registration BC-127102.1 is positioned at 2q22.3, total length 3912bp, wherein CDS sequences 3645bp, encode 1215 amino acid.The tissue expression analysis of spectrum of people source ZEB2 genes is shown:Should Gene has expression in many tumours (stomach cancer, the breast cancer, nasopharyngeal carcinoma etc.) cell and mast cell of people, and research is found, ZEB2 genes also have expression in rat peritoneal macrophages, person monocytic cell THP-1.
Therefore, in order to further study ZEB2 gene functions, being badly in need of one kind at present contributes to ZEB2 gene functional research, and And the useful biology tool of Research foundation is provided effect of the inflammation in the AKI courses of disease for it.
The content of the invention
Contribute to ZEB2 gene functional research it is an object of the invention to overcome the deficiencies of the prior art and provide one kind, And for its effect of the inflammation in the AKI courses of disease is provided Research foundation overexpression ZEB2 gene plasmids and its construction method and Using.
The present invention is achieved by the following technical solutions:One kind is overexpressed ZEB2 gene plasmids, by ZEB2 gene C DS sequences The recombination to construct arranged with pEGFP-C2 carrier for expression of eukaryon is formed;Its nucleotides such as sequence table SEQ ID NO:1, positioned at ZEB2 bases 134-3778 of cause;Amino acid sequence such as sequence table SEQ ID NO:Shown in 2.
A kind of method for building above-mentioned overexpression ZEB2 gene plasmids, comprises the following steps:
(1) HK-2 cells are cracked, RNA progress reverse transcriptions is extracted and obtains ZEB2cDNA;
(2) PCR amplifies the CDS sequence fragments of artificial ZEB2 genes;
(3) purifying of the CDS sequence fragments of ZEB2 genes;
(4) BamH I and Xba I double digestions are carried out to the genetic fragment and pEGFP-C2 carrier for expression of eukaryon that are obtained, and It is attached;
(5) connection product is converted into e. coli tg1, and chooses positive colony and cultivated, then extract plasmid.
Extracted in one of preferred embodiment as the present invention, the step (1) after RNA, denaturation treatment is carried out to it, specifically Step is:RNA is placed after 5-10min in 65 DEG C, is transferred in frozen water and places.
One of preferred embodiment as the present invention, reverse transcription reaction is reversed according to RT Master Mix in the step (1) The product description for recording kit is carried out, and the reaction system of reverse transcription includes:5×RT Master Mix、RNA、Nuclease- free Water;Comprise the following steps that:
(1) reaction system is prepared:5×RT Master Mix 2μL+RNA 2μL+Nuclease-free Water 6μL;
(2) above-mentioned reaction system is placed 37 DEG C, and acts on 15min;
(3) above-mentioned reaction system is transferred to 50 DEG C, and acts on 5min;
(4) above-mentioned reaction system is transferred to 98 DEG C, and acts on 5min;
(5) above-mentioned reaction system is transferred to 4 DEG C, frozen after cooling, that is, obtain cDNA.
As one of preferred embodiment of the present invention, PCR expands required upper and lower during CDS sequence fragments in the step (2) Swim primer sequence as follows:
Sense primer:ZEB2-F:5’-GGGGTACCCCATGAAGCAGCCGATCAT-3’
Anti-sense primer:ZEB2-R:5’-GCTCTAGAGCTCACATGCCATCTTCC-3’.
One of preferred embodiment as the present invention, pcr amplification reaction expands according to PrimeSTAR Max in the step (2) Increase enzyme product specification to carry out, PCR reaction system includes:2 × PrimeSTAR Max, cDNA sample, upstream and downstream primer, height Pure water;Comprise the following steps that:
(1) reaction system is prepared:Each μ L of 1 μ L+ high purity waters 22 of the μ L+ primers of 2 × PrimeSTAR Max, 25 μ L+cDNA 1;
(2) PCR instrument device is put into after above-mentioned reaction system is gently mixed, following program operation is set;
(3) above-mentioned PCR primer is subjected to 1.2% agarose gel electrophoresis;
(4) observe result and reclaim target DNA fragment.
One of preferred embodiment as the present invention, ZEB2 PCR primer and pEGFP-C2 carriers are carried out in the step (4) BamH I and Xba I double digestion reaction are carried out according to restriction enzyme product description, and digestion system is as follows:BamH I are limited Property restriction endonuclease processed, Xba I restriction enzymes, 10 × Buffer Tango, ZEB2 PCR primer or pEGFP-C2 carriers;Tool Body step is as follows:
(1) reaction system is prepared:Each 0.5 μ L+ZEB2 of μ L+BamH I and Xba I of 10 × Buffer Tango 2 PCR productions Thing or with each 7 μ L of pEGFP-C2 carriers;
(2) above-mentioned reaction system is placed in 37 DEG C of water-baths, and acts on 4-6h;
(3) above-mentioned digestion products are subjected to 1-1.2% agarose gel electrophoresis;
(4) observe result and reclaim target DNA fragment.
One of preferred embodiment as the present invention, connection method is specific as follows in the step (4):
(1) the μ L of dephosphorylation system 10 are prepared:CIAP1 μ l, 10 × CIAP buffer solutions, 1 μ l, pEGFP-C2 carrier 8 μ l are right Carrier carries out dephosphorylation process;
(2) the μ L of linked system 10 are prepared:The μ l of pEGFP-C2 carriers 0.5,10 × T4 DNA ligases after CIAP dephosphorylations The μ l of 1 μ l, T4DNA ligase of buffer solution, 1 μ l, PCR digestions purified product 7.5;
(3) above-mentioned reaction system is placed in 0.5ml centrifuge tube and mixed, 16 DEG C of water-baths are stayed overnight.
One of preferred embodiment as the present invention, connection product converts the tool into e. coli tg1 in the step (5) Body step is as follows:
(1) the TG1 competent cells for being stored in 80 DEG C of ﹣ are taken out, ice bath adds 10 μ l connection products after thawing, and mixes, ice Upper standing 30min;
(2) 42 DEG C of heat shock 90s, rapid take out puts 3min on ice;
(3) 500 μ l LB nutrient solutions, 37 DEG C, 250rpm shaken cultivations 45min are added;
(4) take out about 100 μ l conversion fluids to be applied on the LB solid mediums with corresponding resistant, 37 DEG C are inverted culture 8- 12h。
A kind of application using above-mentioned overexpression ZEB2 gene plasmids, people is transfected into by the overexpression ZEB2 gene plasmids In HK-2 cell lines, suppress the secretion of inflammatory factor in people's HK-2 cells.
The advantage of the present invention compared with prior art is:
(1) contribute to study ZEB2 gene functions, and effect of the inflammation in the AKI courses of disease has been provided to study it Use biology tool;
(2) gene recombination technology is used, for ZEB2 genes, recombinant eukaryon expression vector pEGFP-C2-ZEB2 is built, and Transfected into people's HK-2 cell lines, research ZEB2 is overexpressed the influence to inflammatory Cytokines Expression in HK-2 cells, to enter one Step research ZEB2 function, and AKI gene therapy are laid a good foundation.
Brief description of the drawings
The structure that Fig. 1 is a kind of carrier for expression of eukaryon pEGFP-C2 of overexpression ZEB2 gene plasmids in embodiment 1 is shown It is intended to;
Fig. 2 is a kind of eucaryon recombinant vector pEGFP- of the construction method of overexpression ZEB2 gene plasmids in embodiment 2 C2-ZEB2 structural representation;
Fig. 3 is a kind of eucaryon recombinant vector pEGFP- of the construction method of overexpression ZEB2 gene plasmids in embodiment 2 C2-ZEB2 digestion identification collection of illustrative plates;
Fig. 4 be a kind of overexpression ZEB2 gene plasmids in embodiment 3 expression during eucaryon recombinant vector pEGFP- Expression figures of the C2-ZEB2 in HEK 293T cells;
Fig. 5 be a kind of transfection group of the application of overexpression ZEB2 gene plasmids in embodiment 4 HK-2 cellular inflammations because The situation map of sub (IL-6, TNF-α) mRNA expressions;
Fig. 6 be a kind of transfection group of the application of overexpression ZEB2 gene plasmids in embodiment 4 HK-2 cellular inflammations because The situation map of sub (IL-6, TNF-α) protein expression level.
Embodiment
Embodiments of the invention are elaborated below, the present embodiment is carried out lower premised on technical solution of the present invention Implement, give detailed embodiment and specific operating process, but protection scope of the present invention is not limited to following implementations Example.
Embodiment 1
The a kind of of the present embodiment is overexpressed ZEB2 gene plasmids, by ZEB2 gene C DS sequences and pEGFP-C2 eukaryotic expressions The recombination to construct of carrier is formed;Its nucleotides such as sequence table SEQ ID NO:1, positioned at 134-3778 of ZEB2 genes;Ammonia Base acid sequence such as sequence table SEQ ID NO:Shown in 2;In addition, the structure of pEGFP-C2 carrier for expression of eukaryon is as shown in Figure 1.
Embodiment 2
A kind of construction method of overexpression ZEB2 gene plasmids of the present embodiment, comprises the following steps:
1st, ZEB2cDNA extraction
(1) take out Tissue Culture Dish and abandon net culture medium, the cell of the HK-2 cells of culture is cleaned with 1ml PBS Face (2-3 times);
(2) 1ml Trizol cell lysis 10min are added, are gently mixed cell pyrolysis liquid turn with pipettor after cell Move in centrifuge tube, 5min is stored at room temperature after reverse mixing;
(3) chloroform (4 DEG C of precoolings) of Trizol 1/5 amount is added, 5min is stored at room temperature after acutely mixing, high speed is low Temperature centrifugation 15min (4 DEG C, 12000r/min);
(4) 0.4ml supernatant liquids are transferred in new centrifuge tube, add isometric isopropanol, overturn quiet after mixing Supernatant is abandoned after putting 60min (- 20 DEG C), high-speed low temperature centrifugation 15min (4 DEG C, 12000r/min);
(5) vibrate and mix after the ethanol solution for adding 1ml75%, after high-speed low temperature centrifugation 5min (4 DEG C, 12000r/min) Supernatant is abandoned, and dries 5min;
(6) after adding 20 μ L without enzyme water dissolving precipitation, for reverse transcription, it can also freeze in -80 degree;
(7) RNA denaturation
The RNA extracted is denatured, denaturing step is as follows:RNA is placed after 5min in 65 DEG C, is transferred quickly to 2min is placed in frozen water.
Reverse transcription reaction system (10 μ L) is as follows:
Processing step includes:
1. above-mentioned reaction system is placed 37 DEG C, and acts on 15min;
2. above-mentioned reaction system is transferred to 50 DEG C, and acts on 5min;
3. above-mentioned reaction system is transferred to 98 DEG C, and acts on 5min;
4. above-mentioned reaction system is transferred to 4 DEG C, frozen after cooling, that is, obtain cDNA.
2nd, the clone of ZEB2 genes
(1) according to ZEB2 CDS sequences, upstream and downstream primer is designed, primer sequence difference is as follows:
ZEB2-F:5 '-GGGGTACCCCATGAAGCAGCCGATCAT-3 ' (restriction enzyme sites of I containing BamH)
ZEB2-R:5 '-GCTCTAGAGCTCACATGCCATCTTCC-3 ' (restriction enzyme sites of I containing Xba)
(2) enzyme used in the process of PCR is preferably the PrimeSTAR Max high-fidelity enzymes of Takara companies, its reactant System and response procedures are as follows:
Reaction system (50 μ L):
PCR instrument device is put into after above-mentioned reaction system is mixed, following program operation is set:
(3) above-mentioned PCR primer is subjected to 1.2% agarose gel electrophoresis;
(4) observe result and reclaim target DNA fragment;
PCR primer is entered into row agarose gel electrophoresis, by the contrast with DNA Marker, as a result finds to go out in 3645bp A band is obtained, size and the size of ZEB2 purpose fragments (including restriction enzyme site) are basically identical, show that Successful amplification goes out people The CDS sequences of ZEB2 genes.
3rd, the purifying of ZEB2 purpose fragments
Purifying kit used is preferably that love is pursued progress the glue reclaim kit of company, and purification step is as follows:
(1) Ago-Gel containing target DNA is cut under uviol lamp, gel surface liquid is exhausted with filter paper and cuts It is broken.Calculated for gel weight, 100 μ l volumes are equal to per 100mg;
(2) the Buffer DE-A of 3 gel volumes are added, is well mixed and heats (low melting-point agarose gel after 75 DEG C Heated in 40 DEG C), interruption mixing (every 2~3min), until gel piece is completely melt;
(3) add the Buffer DE-B of 0.5 Buffer DE-A volume, be well mixed.When the DNA fragmentation of separation is less than During 400bp, the isopropanol of 1 gel volume need to be added;
(4) mixed liquor in aspiration step 3, is transferred to DNA and prepares in pipe (being placed in 2ml centrifuge tubes), 12,000rpm centrifugations 1min.Abandon filtrate;
(5) pipe will be prepared and put back into 2ml centrifuge tubes, plus 500 μ l Buffer W1,12,000rpm centrifugation 30s, filtrate is abandoned;
(6) pipe will be prepared and put back into 2ml centrifuge tubes, plus 700 μ l Buffer W2,12,000rpm centrifugation 30s, filtrate is abandoned;With Same method washed once 12,000rpm centrifugations 1min with 700 μ l Buffer W2 again;
(7) pipe will be prepared to put back into 2ml centrifuge tubes, 12,000rpm centrifugation 1min;
(8) pipe will be prepared to be placed in the 1.5ml centrifuge tubes of cleaning, is preparing film center plus 30 μ l Eluent or deionization Water, is stored at room temperature 1min.12000rpm centrifuges 1min eluted dnas.
4th, the double digestion of PCR primer and carrier for expression of eukaryon
PCR primer and pEGFP-C2 carriers to ZEB2 carry out BamH I and Xba I double digestion, digestion system and method It is as follows:
Digestion system (10 μ L):
Enzymatic cleavage methods:Above reaction system is placed in 0.5ml centrifuge tube and mixed, 37 DEG C of water-bath 6h (temperature and times Selection gist restriction endonuclease specification depending on), rapid observation result and reclaim target DNA after 1.2% agarose gel electrophoresis Fragment, it is to avoid ultraviolet long-term irradiation.
5th, the connection of digestion products
ZEB2 and pEGFP-C2 double digestion product is attached, connection enzyme used is preferably T4 ligases;Even Before connecing, to avoid the recirculation of carrier, therefore dephosphorylation process is carried out to carrier;
Dephosphorylation system (10 μ L):The μ l of CIAP 1, the μ l of 10 × CIAP buffer solutions, 1 μ l, pEGFP-C2 carrier 8;
Linked system (10 μ L):The μ l of pEGFP-C2 carriers 0.5,10 × T4DNA connection enzyme buffers after CIAP dephosphorylations The μ l of 1 μ l, T4DNA ligase of liquid, 1 μ l, PCR digestions purified product 7.5;
Connection method:Above-mentioned reaction system is placed in 0.5ml centrifuge tube and mixed, 16 DEG C of water-baths are stayed overnight.
6th, the conversion of connection product
Converting E. coli competent used is:TG1, step of converting is as follows:
(1) the TG1 competent cells for being stored in 80 DEG C of ﹣ are taken out, ice bath adds 10 μ l connection products after thawing, gently mixed It is even, 30min is stood on ice;
(2) 42 DEG C of heat shock 90s (should not rock), rapid take out puts 3min on ice;
(3) 500 μ l LB nutrient solutions, 37 DEG C, 250rpm shaken cultivations 45min are added;
(4) take out about 100 μ l conversion fluids to be applied on the LB solid mediums with corresponding resistant, 37 DEG C are inverted culture 12h.
7th, a small amount of extractings of plasmid
Choose 8 positive colonies to add in the centrifuge tubes containing 2ml LB culture mediums (ammonia benzyl resistance), 37 DEG C, 250rpm shakes Culture 12h is swung, plasmid extraction is then carried out to bacterium solution, kit used is pursued progress the small amount plasmid extraction agent of company for love Box, extraction steps are as follows:
(1) with the monoclonal of sterilizing toothpick picking bacterium, it is put into the 15ml for containing the LB nutrient solutions that 2ml contains corresponding antibiotic In centrifuge tube, 37 DEG C, 250rpm shaken cultivations 12h;
(2) about 1ml bacterium solutions are transferred in 1.5ml centrifuge tubes, 4 DEG C, 12,000rpm centrifugation 1min, supernatant;
(3) 250 μ l Buffer S1 suspended bacterials precipitation is added, suspending, it is uniform to need, and should not leave small fungus block;
(4) it is plus 250 μ l Buffer S2, gentle and fully spinning upside down 6 times makes thalline fully crack, until being formed thoroughly Bright solution;
(5) add 350 μ l Buffer S3, spin upside down gently and fully mixing 8 times, 12,000rpm centrifugation 10min;
(6) centrifugation supernatant in aspiration step 5 is simultaneously transferred to preparation pipe (being placed in 2ml centrifuge tubes), 12000rpm centrifugations 1min, abandons filtrate;
(7) pipe will be prepared and put back into centrifuge tube, plus 500 μ l Buffer W1,12,000rpm centrifugation 1min, filtrate is abandoned;
(8) pipe will be prepared and put back into centrifuge tube, plus 700 μ l Buffer W2,12,000rpm centrifugation 1min, filtrate is abandoned;With same The method of sample washed once with 700 μ l Buffer W2 again.Abandon filtrate;
(9) pipe will be prepared to put back into 2ml centrifuge tubes, 12,000rpm centrifugation 1min;
(10) pipe will be prepared to move into new 1.5ml centrifuge tubes, is preparing periosteum center plus 80 μ l sterilized waters, be stored at room temperature 1min, 12,000rpm centrifugation 1min, abandons preparation pipe;
(11) sample put -20 DEG C it is standby, Fig. 2 be eucaryon recombinant vector pEGFP-C2-ZEB2 structural representation.
8th, digestion identification is carried out to plasmid and send sequencing
BamH I and Xba I double digestion identification are carried out to the plasmid extracted, digestion system and method are as follows:
Digestion system (10 μ L):
Enzymatic cleavage methods:Above-mentioned reaction system is placed in 0.5ml centrifuge tube and mixed, after 37 DEG C of digestion 6h, agarose coagulates Preservation that gel electrophoresis, ultraviolet spectrometer are observed, gel imager is taken pictures, and correct plasmid Song Sheng works biotech firm is identified into digestion Sequencing;Wherein, eucaryon recombinant vector pEGFP-C2-ZEB2 digestion identification collection of illustrative plates is shown in Fig. 3, wherein sign 1 is pEGFP-C2 double Digestion, sign 2 is ZEB2 PCR primer, and sign 3 is pEGFP-C2-ZEB2 double digestions;
Sequencing result is compared by BLAST, target gene piece segment length consistent with the sequence announced in GencBank is found Spend actually 3645bp.
Embodiment 3
A kind of expression of overexpression ZEB2 gene plasmids, obtains being overexpressed after ZEB2 gene plasmids, to it according to embodiment 2 Expressed, comprised the following steps that:
1st, cell culture
The cell of culture is needed for of the invention:HEK, 293T, THP-1, rat peritoneal macrophages, HK-2 cells, first Recovery cell, and with containing volume ratio for 10% hyclone DMEM high glucose mediums in 37 DEG C, 5%CO2 cell culture Cultivated in case, and change liquid and passage in time.
(1) cell recovery:The cell frozen in liquid nitrogen is taken out, immerses rapidly in 37 DEG C of warm water and jiggles to complete Complete to melt (rewarming time was controlled within two minutes), rapid transfer cell suspension is into centrifuge tube and adds 5ml culture mediums, Abandon most supernatant after low-speed centrifugal (1 000r/min, 2min), add 5ml culture mediums and be gently seeded in culture dish after suspension cell Start culture;
(2) cell changes liquid:Old cell culture medium is gently discarded, PBS adds fresh complete medium after gently cleaning (DMEM in high glucose containing 10% hyclone) continues to cultivate (note:PBS and fresh culture medium need 37 DEG C of preheatings);
(3) passage:It is placed in incubator and is digested after the pancreatin that 1ml is added in cell, is seen under the microscope Cellular morphology change is examined, complete medium is added in time and terminates digestion, transfer cell suspension low-speed centrifugal (1 into centrifuge tube 000r/min, 2min) after abandon supernatant, 0.2ml culture mediums suspension cell is added after washed once with PBS and culture is seeded to again Continue to cultivate in ware;
(4) cell cryopreservation:Supernatant will be abandoned after cell suspension low-speed centrifugal (1 000r/min, 2min) in succeeding generations, Add 1ml cells frozen storing liquids (formula is shown in) and gently dispense into cell cryopreservation tube after suspension cell and carry out classification and freeze, i.e., 4 DEG C 0.5-1h, -20 DEG C of 1-2h, -80 DEG C of about 24h, liquid nitrogen cryopreservations.
2nd, plasmid transiently transfects (liposome method)
(1) DNA that 5 μ l liposome and total amount are about 2 μ g is diluted with 250 μ L Opti-MEM, gentle to mix, room temperature is quiet Put 5min;
(2) two kinds of solution in above-mentioned steps are gently mixed, is stored at room temperature 20min, to form DNA- lipid bluk recombinations Thing;
(3) nutrient solution in culture dish is discarded, 1ml Opti-MEM transfection liquids are added, the DNA- liposomes in (2) are answered Compound is slowly dropped in culture dish, jiggles culture dish mixing;
(4) 37 DEG C, 5%CO2Cultivate after 6h, renew and continue to train after fresh complete culture solution with the PBS of pre-temperature once Support about 24h.
3rd, immunoblotting analysis
(1) total protein extraction:Cell is collected by centrifugation, after PBS 2-3 times, 0.5ml cell pyrolysis liquids are added, on ice 10min is cracked, then high speed refrigerated centrifuge 10min, collect 0.4ml supernatants, add sample-loading buffer, boiling water bath 5min is put Put and treat electrophoresis on ice;
(2) glue plate is installed and hunted leak, 10% separation gel is prepared first, with 1ml isopropanol line balls, after after abundant solidification (about 1h), prepares concentration glue, and comb needed for insertion is used after after abundant solidification;
(3) electrophoresis system is installed, 500ml electrophoretic buffers are added in electrophoresis tank, 10 μ L samples are added behind loading hole Start electrophoresis (80V electrophoresis 0.5h+100V electrophoresis 1.5h);
(4) after electrophoresis terminates, cut SDS-PAGE glue, using sandwich mode (be successively from the bottom up filter paper+glue+ Pvdf membrane+filter paper) carry out wet turn;
(5) electricity is installed and transfers from one department to another system, the electricity that 500ml precoolings are added in electric turn trough turns buffer solution, and whole electric turn trough is put Enter in frozen water, start electricity and turn (100V electricity turns 2h);
(6) whether electricity turns after terminating, and gently removes pvdf membrane, succeeded with Ponceaux dyeing identification transferring film, after transferring film success, Ponceaux, room temperature closing at least 1h are washed away with TBST;
(7) after having closed, washed with TBST after film (3 times, 5min), add 4 DEG C of overnight incubations of primary antibody solution;
(8) next day, washed with TBST after film (3 times, 10min), add two corresponding anti-solution incubation at room temperature 2h.Then film is washed with TBST (3 times, 20min);
(9) with the band on ECL luminous agents detection PVDF, and X-ray film scotography is used.
Experimental result shows, recombinant eukaryotic expression plasmid pEGFP-C2-ZEB2 in eukaryotic can normal expression, be Follow-up research is laid a good foundation;Fig. 4 is expressions of the eucaryon recombinant vector pEGFP-C2-ZEB2 in HEK293T cells In figure, figure, sign 1 is the 293T cell pyrolysis liquids of untransfected, the 293T cells cracking that sign 2 is transfection pEGFP-C2-ZEB2 Liquid.
Embodiment 4
A kind of application of overexpression ZEB2 gene plasmids, people's HK-2 cells are transfected into by the overexpression ZEB2 gene plasmids In system, research is overexpressed the influence of ZEB2 gene pairs people's HK-2 cell lines inflammatory factors (IL-6, TNF-α) secretion;Specific steps It is as follows:
1st, the cell of exponential phase is passed on, obtains cell suspension, and with suitable density (about 1 × 108L-1) Seed cells into 6 orifice plates, cultivate about 24h, until cell density is 80% or so, carry out the instantaneous of pEGFP-C2-ZEB2 Transfection, cell suspension is collected after transfection a period of time;
2nd, according to the specification of manufacturer, total serum IgE is separated from culture HK-2 cells using Trizol reagents, always Water elutions of the RNA without RNase, and it is stored in -80 DEG C;
3rd, cDNA is synthesized using transcripton the first chain cDNA synthetic agent box, and using with SYBR-Green Master Mix detecting system carries out real-time PCR, and q-PCR primers are obtained from Invitrogen, and two parts of sample, every time measurement is repeated At least three times, q-PCR results are as shown in Figure 5;
Fig. 5 A qRT-PCR analysis shows:ZEB2 expression has been raised in pEGFP-C2-ZEB2 transfection;Fig. 5 B's QRT-PCR analysis shows:TNF-α and IL-6 expression (* P have been lowered in pEGFP-C2-ZEB2 transfection<0.05 and * *, P< 0.01vs normal groups;#P<0.05 and ##P<0.01vs empty plasmids group);
Find based on the above results:Compared with inflammatory factor (IL-6, TNF-α) mRNA level in-site of untransfected group cell, turn Having contaminated the expression of inflammatory factor IL-6 and TNF-α mRNA in the HK-2 cells of pEGFP-C2-ZEB2 groups has obvious reduction, and poor It is different to there is statistical significance (P < 0.05);Illustrate that inflammatory factor (IL-6, TNF-α) can substantially be reduced by being overexpressed ZEB2 genes MRNA level in-site, so as to suppress inflammatory reaction.
In addition, extracting total protein and detectable concentration, gel electrophoresis is carried out, it is wet to turn after nitrocellulose membrane, use 5% skim milk 60min is closed, 1 is added:The ZEB2 rabbit-antis of 200 dilutions, 1:IL-6, TNF-α and the Beta- of 1: 1 000 dilution of 1000 dilutions After Actin internal reference primary antibodies, 4 DEG C of overnight incubations are rinsed 3 times with TBST, add the secondary antibody of respective concentration, 60min is placed at room temperature, TBST is rinsed 3 times, adds development under the conditions of ECL Plus, scotopia, protein band is analyzed with Quantity One softwares, Western blot results are as shown in Figure 6;
Fig. 6 A Western blot analysis shows:ZEB2 expression has been raised in pEGFP-C2-ZEB2 transfection;Fig. 6 B Western blot analysis shows, pEGFP-C2-ZEB2 transfection lowered TNF-α and IL-6 expression (* P<0.05 With * * P<0.01 compared with normal group;#P<0.05 and ##P<0.01 compared with vector groups);
Find based on the above results:Compared with inflammatory factor (IL-6, TNF-α) protein level of untransfected group cell, turn Having contaminated inflammatory factor (IL-6, TNF-α) albumen of the cell of pEGFP-C2-ZEB2 groups has obvious reduction, and difference has system Meter learns meaning (P < 0.05);Illustrate that inflammatory factor (IL-6, TNF-α) protein level can substantially be reduced by being overexpressed ZEB2 genes, So as to suppress inflammatory reaction.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention Any modifications, equivalent substitutions and improvements made within refreshing and principle etc., should be included in the scope of the protection.
SEQUENCE LISTING
<110>Medical University Of Anhui
<120>One kind is overexpressed ZEB2 gene plasmids and its construction method and application
<130> 2017
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 3645
<212> DNA
<213> human
<400> 1
atgaagcagc cgatcatggc ggatggcccc cggtgcaaga ggcgcaaaca agccaatccc 60
aggaggaaaa acgtggtgaa ctatgacaat gtagtggaca caggttctga aacagatgag 120
gaagacaagc ttcatattgc tgaggatgac ggtattgcca accctctgga ccaggagacg 180
agtccagcta gtgtgcccaa ccatgagtcc tccccacacg tgagccaagc tctgttgcca 240
agagaggaag aggaagatga aataagggag ggtggagtgg aacacccctg gcacaacaac 300
gagattctac aagcctctgt agatggtcca gaagaaatga aggaagacta tgacactatg 360
gggccagaag ccacgatcca gaccgcaatt aacaatggta cagtgaagaa tgcaaattgc 420
acatcagatt ttgaggaata ctttgccaaa agaaaactgg aggaacgcga tggtcatgca 480
gtcagcatcg aggagtacct tcagcgcagt gacacagcca ttatttaccc agaagcccct 540
gaggagctgt ctcgccttgg cacgccagag gccaatgggc aagaagaaaa tgacctgcca 600
cctggaactc cagatgcttt tgcccaactg ctgacctgcc cctactgcga ccggggctac 660
aagcgcttga catcactgaa ggagcacatc aagtaccgcc acgagaagaa tgaagagaac 720
ttttcctgcc ctctctgtag ctacacgttt gcctaccgca cccagctcga gcggcatatg 780
gtgacacaca agccagggac agatcagcac caaatgctaa cccaaggagc aggtaatcgc 840
aagttcaaat gcacagagtg tggcaaggcc ttcaaatata aacaccatct gaaagaacac 900
ctgcgaattc acagtggtga aaaaccttac gagtgcccaa actgcaagaa acgtttctcc 960
cattctggtt cctacagttc gcacatcagc agcaagaaat gtattggttt aatctctgta 1020
aatggccgaa tgagaaacaa tatcaagacg ggttcttccc ctaattctgt ttcttcttct 1080
cctactaatt cagccattac ccagttaaga aacaagttgg agaatggaaa accacttagt 1140
atgtctgaac agacaggctt acttaaaatt aaaacagaac cactagactt caatgactat 1200
aaagttctta tggctacaca cgggtttagt ggcactagtc cctttatgaa tggtgggctt 1260
ggagccacca gccctttagg agttcatcca tctgctcaga gtccaatgca gcacttaggt 1320
gtagggatgg aagccccttt acttgggttt cccaccatga atagtaattt aagtgaggta 1380
caaaaggttc tacagattgt ggacaatact gtttccaggc aaaaaatgga ctgcaaggct 1440
gaagaaattt caaagttgaa aggttatcac atgaaggatc catgctctca acctgaggaa 1500
caaggagtta cttctcctaa tattccgcct gtcggtcttc cggtagtgag tcataatggt 1560
gccactaaaa gtattattga ctatacgttg gaaaaagtca atgaagccaa agcttgcctc 1620
cagagcttga ctactgactc aaggagacag atcagtaata taaagaaaga gaagctacgt 1680
actttaatag atttggtcac tgatgacaaa atgattgaga accacaacat atccactcca 1740
ttttcatgcc agttctgtaa agaaagtttt cctggcccca tccctttgca tcagcatgaa 1800
cgttaccttt gtaagatgaa tgaagagatc aaggcggtcc tgcagcctca tgaaaacata 1860
gtccccaaca aagccggagt ttttgttgat aataaagccc tcctcttgtc atctgtactt 1920
tctgagaaag gaatgacaag ccccatcaac ccatacaagg accacatgtc tgtactcaaa 1980
gcatactatg ctatgaacat ggagcccaac tccgatgaac tgctgaaaat ttccattgct 2040
gtgggccttc ctcaggaatt tgtgaaggaa tggtttgaac aacgaaaagt ctaccagtac 2100
tcaaattcca ggtccccatc cctggaaaga agctccaagc cgttagctcc caacagtaac 2160
cctcccacaa aagactcttt attacccagg tctcctgtaa aacctatgga ctccataaca 2220
tcaccatcta tagcagaact ccacaacagt gttacgaatt gtgatcctcc tctcaggcta 2280
acaaaacctt cccattttac caatattaaa ccagttgaaa aattggacca ctccaggagt 2340
aatactcctt ctcccttaaa tctttcctcc acatcttcta aaaactccca cagtagttca 2400
tacactccaa acagcttctc ttctgaggag ctccaggctg agcctttaga cttgtcatta 2460
ccaaaacaaa tgaaagaacc caaaagtatt atagccacaa agaacaaaac aaaagctagt 2520
agcatcagtt tagatcataa cagtgtttct tcctcatctg aaaactcaga tgagcctctg 2580
aacttgactt ttatcaagaa ggaattttca aattcaaata atctggacaa caaaagcact 2640
aacccagtgt tcagcatgaa cccatttagt gccaaacctt tatacacagc tcttccacct 2700
caaagcgcat ttccccctgc tactttcatg ccaccagtcc agaccagtat tcctgggcta 2760
cgaccatacc caggactgga tcagatgagc ttcctaccac atatggccta cacctaccca 2820
actggagcag ctacttttgc tgatatgcag caaaggagaa agtaccagcg gaaacaagga 2880
tttcagggag aattgcttga tggagcacaa gactacatgt caggcctaga tgatatgaca 2940
gactccgact cctgtctgtc tcgcaaaaag atcaagaaga cagagagtgg catgtatgca 3000
tgtgacttat gtgacaagac attccagaaa agcagttccc ttctgcgaca taaatacgaa 3060
cacacaggaa aaagaccaca tcagtgtcag atttgtaaga aagcgtttaa acacaagcac 3120
caccttatcg agcactcaag gcttcactcg ggcgagaagc cctatcagtg tgataaatgt 3180
ggcaagcgct tctcacactc gggctcgtac tcgcagcaca tgaatcacag gtattcctac 3240
tgcaagcggg aggcggagga gcgggaagcg gcggagcgcg aggcgcgcga gaaagggcac 3300
ttggaaccca ccgagctgct gatgaaccgg gcttacttgc agagcattac ccctcagggg 3360
tactctgact cggaggagag ggagagtatg ccgagggatg gcgagagcga gaaggagcac 3420
gagaaagaag gcgaggatgg ctacgggaag ctgggcagac aggatggcga cgaggagttc 3480
gaggaggaag aggaagaaag tgaaaataaa agtatggata cggatcccga aacgatacga 3540
gatgaagaag agactggaga tcactccatg gacgatagtt cggaggatgg gaaaatggaa 3600
accaaatcag accacgagga agacaatatg gaagatggca tgtaa 3645
<210> 2
<211> 1214
<212> PRT
<213> human
<400> 2
Met Lys Gln Pro Ile Met Ala Asp Gly Pro Arg Cys Lys Arg Arg Lys
1 5 10 15
Gln Ala Asn Pro Arg Arg Lys Asn Val Val Asn Tyr Asp Asn Val Val
20 25 30
Asp Thr Gly Ser Glu Thr Asp Glu Glu Asp Lys Leu His Ile Ala Glu
35 40 45
Asp Asp Gly Ile Ala Asn Pro Leu Asp Gln Glu Thr Ser Pro Ala Ser
50 55 60
Val Pro Asn His Glu Ser Ser Pro His Val Ser Gln Ala Leu Leu Pro
65 70 75 80
Arg Glu Glu Glu Glu Asp Glu Ile Arg Glu Gly Gly Val Glu His Pro
85 90 95
Trp His Asn Asn Glu Ile Leu Gln Ala Ser Val Asp Gly Pro Glu Glu
100 105 110
Met Lys Glu Asp Tyr Asp Thr Met Gly Pro Glu Ala Thr Ile Gln Thr
115 120 125
Ala Ile Asn Asn Gly Thr Val Lys Asn Ala Asn Cys Thr Ser Asp Phe
130 135 140
Glu Glu Tyr Phe Ala Lys Arg Lys Leu Glu Glu Arg Asp Gly His Ala
145 150 155 160
Val Ser Ile Glu Glu Tyr Leu Gln Arg Ser Asp Thr Ala Ile Ile Tyr
165 170 175
Pro Glu Ala Pro Glu Glu Leu Ser Arg Leu Gly Thr Pro Glu Ala Asn
180 185 190
Gly Gln Glu Glu Asn Asp Leu Pro Pro Gly Thr Pro Asp Ala Phe Ala
195 200 205
Gln Leu Leu Thr Cys Pro Tyr Cys Asp Arg Gly Tyr Lys Arg Leu Thr
210 215 220
Ser Leu Lys Glu His Ile Lys Tyr Arg His Glu Lys Asn Glu Glu Asn
225 230 235 240
Phe Ser Cys Pro Leu Cys Ser Tyr Thr Phe Ala Tyr Arg Thr Gln Leu
245 250 255
Glu Arg His Met Val Thr His Lys Pro Gly Thr Asp Gln His Gln Met
260 265 270
Leu Thr Gln Gly Ala Gly Asn Arg Lys Phe Lys Cys Thr Glu Cys Gly
275 280 285
Lys Ala Phe Lys Tyr Lys His His Leu Lys Glu His Leu Arg Ile His
290 295 300
Ser Gly Glu Lys Pro Tyr Glu Cys Pro Asn Cys Lys Lys Arg Phe Ser
305 310 315 320
His Ser Gly Ser Tyr Ser Ser His Ile Ser Ser Lys Lys Cys Ile Gly
325 330 335
Leu Ile Ser Val Asn Gly Arg Met Arg Asn Asn Ile Lys Thr Gly Ser
340 345 350
Ser Pro Asn Ser Val Ser Ser Ser Pro Thr Asn Ser Ala Ile Thr Gln
355 360 365
Leu Arg Asn Lys Leu Glu Asn Gly Lys Pro Leu Ser Met Ser Glu Gln
370 375 380
Thr Gly Leu Leu Lys Ile Lys Thr Glu Pro Leu Asp Phe Asn Asp Tyr
385 390 395 400
Lys Val Leu Met Ala Thr His Gly Phe Ser Gly Thr Ser Pro Phe Met
405 410 415
Asn Gly Gly Leu Gly Ala Thr Ser Pro Leu Gly Val His Pro Ser Ala
420 425 430
Gln Ser Pro Met Gln His Leu Gly Val Gly Met Glu Ala Pro Leu Leu
435 440 445
Gly Phe Pro Thr Met Asn Ser Asn Leu Ser Glu Val Gln Lys Val Leu
450 455 460
Gln Ile Val Asp Asn Thr Val Ser Arg Gln Lys Met Asp Cys Lys Ala
465 470 475 480
Glu Glu Ile Ser Lys Leu Lys Gly Tyr His Met Lys Asp Pro Cys Ser
485 490 495
Gln Pro Glu Glu Gln Gly Val Thr Ser Pro Asn Ile Pro Pro Val Gly
500 505 510
Leu Pro Val Val Ser His Asn Gly Ala Thr Lys Ser Ile Ile Asp Tyr
515 520 525
Thr Leu Glu Lys Val Asn Glu Ala Lys Ala Cys Leu Gln Ser Leu Thr
530 535 540
Thr Asp Ser Arg Arg Gln Ile Ser Asn Ile Lys Lys Glu Lys Leu Arg
545 550 555 560
Thr Leu Ile Asp Leu Val Thr Asp Asp Lys Met Ile Glu Asn His Asn
565 570 575
Ile Ser Thr Pro Phe Ser Cys Gln Phe Cys Lys Glu Ser Phe Pro Gly
580 585 590
Pro Ile Pro Leu His Gln His Glu Arg Tyr Leu Cys Lys Met Asn Glu
595 600 605
Glu Ile Lys Ala Val Leu Gln Pro His Glu Asn Ile Val Pro Asn Lys
610 615 620
Ala Gly Val Phe Val Asp Asn Lys Ala Leu Leu Leu Ser Ser Val Leu
625 630 635 640
Ser Glu Lys Gly Met Thr Ser Pro Ile Asn Pro Tyr Lys Asp His Met
645 650 655
Ser Val Leu Lys Ala Tyr Tyr Ala Met Asn Met Glu Pro Asn Ser Asp
660 665 670
Glu Leu Leu Lys Ile Ser Ile Ala Val Gly Leu Pro Gln Glu Phe Val
675 680 685
Lys Glu Trp Phe Glu Gln Arg Lys Val Tyr Gln Tyr Ser Asn Ser Arg
690 695 700
Ser Pro Ser Leu Glu Arg Ser Ser Lys Pro Leu Ala Pro Asn Ser Asn
705 710 715 720
Pro Pro Thr Lys Asp Ser Leu Leu Pro Arg Ser Pro Val Lys Pro Met
725 730 735
Asp Ser Ile Thr Ser Pro Ser Ile Ala Glu Leu His Asn Ser Val Thr
740 745 750
Asn Cys Asp Pro Pro Leu Arg Leu Thr Lys Pro Ser His Phe Thr Asn
755 760 765
Ile Lys Pro Val Glu Lys Leu Asp His Ser Arg Ser Asn Thr Pro Ser
770 775 780
Pro Leu Asn Leu Ser Ser Thr Ser Ser Lys Asn Ser His Ser Ser Ser
785 790 795 800
Tyr Thr Pro Asn Ser Phe Ser Ser Glu Glu Leu Gln Ala Glu Pro Leu
805 810 815
Asp Leu Ser Leu Pro Lys Gln Met Lys Glu Pro Lys Ser Ile Ile Ala
820 825 830
Thr Lys Asn Lys Thr Lys Ala Ser Ser Ile Ser Leu Asp His Asn Ser
835 840 845
Val Ser Ser Ser Ser Glu Asn Ser Asp Glu Pro Leu Asn Leu Thr Phe
850 855 860
Ile Lys Lys Glu Phe Ser Asn Ser Asn Asn Leu Asp Asn Lys Ser Thr
865 870 875 880
Asn Pro Val Phe Ser Met Asn Pro Phe Ser Ala Lys Pro Leu Tyr Thr
885 890 895
Ala Leu Pro Pro Gln Ser Ala Phe Pro Pro Ala Thr Phe Met Pro Pro
900 905 910
Val Gln Thr Ser Ile Pro Gly Leu Arg Pro Tyr Pro Gly Leu Asp Gln
915 920 925
Met Ser Phe Leu Pro His Met Ala Tyr Thr Tyr Pro Thr Gly Ala Ala
930 935 940
Thr Phe Ala Asp Met Gln Gln Arg Arg Lys Tyr Gln Arg Lys Gln Gly
945 950 955 960
Phe Gln Gly Glu Leu Leu Asp Gly Ala Gln Asp Tyr Met Ser Gly Leu
965 970 975
Asp Asp Met Thr Asp Ser Asp Ser Cys Leu Ser Arg Lys Lys Ile Lys
980 985 990
Lys Thr Glu Ser Gly Met Tyr Ala Cys Asp Leu Cys Asp Lys Thr Phe
995 1000 1005
Gln Lys Ser Ser Ser Leu Leu Arg His Lys Tyr Glu His Thr Gly
1010 1015 1020
Lys Arg Pro His Gln Cys Gln Ile Cys Lys Lys Ala Phe Lys His
1025 1030 1035
Lys His His Leu Ile Glu His Ser Arg Leu His Ser Gly Glu Lys
1040 1045 1050
Pro Tyr Gln Cys Asp Lys Cys Gly Lys Arg Phe Ser His Ser Gly
1055 1060 1065
Ser Tyr Ser Gln His Met Asn His Arg Tyr Ser Tyr Cys Lys Arg
1070 1075 1080
Glu Ala Glu Glu Arg Glu Ala Ala Glu Arg Glu Ala Arg Glu Lys
1085 1090 1095
Gly His Leu Glu Pro Thr Glu Leu Leu Met Asn Arg Ala Tyr Leu
1100 1105 1110
Gln Ser Ile Thr Pro Gln Gly Tyr Ser Asp Ser Glu Glu Arg Glu
1115 1120 1125
Ser Met Pro Arg Asp Gly Glu Ser Glu Lys Glu His Glu Lys Glu
1130 1135 1140
Gly Glu Asp Gly Tyr Gly Lys Leu Gly Arg Gln Asp Gly Asp Glu
1145 1150 1155
Glu Phe Glu Glu Glu Glu Glu Glu Ser Glu Asn Lys Ser Met Asp
1160 1165 1170
Thr Asp Pro Glu Thr Ile Arg Asp Glu Glu Glu Thr Gly Asp His
1175 1180 1185
Ser Met Asp Asp Ser Ser Glu Asp Gly Lys Met Glu Thr Lys Ser
1190 1195 1200
Asp His Glu Glu Asp Asn Met Glu Asp Gly Met
1205 1210

Claims (10)

1. one kind is overexpressed ZEB2 gene plasmids, it is characterised in that carried by ZEB2 gene C DS sequences and pEGFP-C2 eukaryotic expressions The recombination to construct of body is formed;Its nucleotides such as sequence table SEQ ID NO:1, positioned at 134-3778 of ZEB2 genes;Amino Acid sequence such as sequence table SEQ ID NO:Shown in 2.
2. a kind of build the method as claimed in claim 1 for being overexpressed ZEB2 gene plasmids, it is characterised in that including following step Suddenly:
(1) HK-2 cells are cracked, RNA progress reverse transcriptions is extracted and obtains ZEB2cDNA;
(2) PCR amplifies the CDS sequence fragments of artificial ZEB2 genes;
(3) purifying of the CDS sequence fragments of ZEB2 genes;
(4) BamH I and Xba I double digestions are carried out to the genetic fragment and pEGFP-C2 carrier for expression of eukaryon that are obtained, and carried out Connection;
(5) connection product is converted into e. coli tg1, and chooses positive colony and cultivated, then extract plasmid.
3. the construction method of overexpression ZEB2 gene plasmids according to claim 2, it is characterised in that the step (1) After middle extraction RNA, denaturation treatment is carried out to it, concretely comprised the following steps:RNA is placed after 5-10min in 65 DEG C, frozen water is transferred to It is middle to place.
4. the construction method of overexpression ZEB2 gene plasmids according to claim 2, it is characterised in that the step (1) Middle reverse transcription reaction is carried out according to the product description of RT Master Mix Reverse Transcriptase kits, the reaction system bag of reverse transcription Include:5×RT Master Mix、RNA、Nuclease-free Water;Comprise the following steps that:
(1) reaction system is prepared:5×RT Master Mix 2μL+RNA 2μL+Nuclease-free Water 6μL;
(2) above-mentioned reaction system is placed 37 DEG C, and acts on 15min;
(3) above-mentioned reaction system is transferred to 50 DEG C, and acts on 5min;
(4) above-mentioned reaction system is transferred to 98 DEG C, and acts on 5min;
(5) above-mentioned reaction system is transferred to 4 DEG C, frozen after cooling, that is, obtain cDNA.
5. the construction method of overexpression ZEB2 gene plasmids according to claim 2, it is characterised in that the step (2) Required upstream and downstream primer sequence is as follows during middle PCR amplifications CDS sequence fragments:
Sense primer:ZEB2-F:5’-GGGGTACCCCATGAAGCAGCCGATCAT-3’
Anti-sense primer:ZEB2-R:5’-GCTCTAGAGCTCACATGCCATCTTCC-3’.
6. the construction method of overexpression ZEB2 gene plasmids according to claim 2, it is characterised in that the step (2) Middle pcr amplification reaction is carried out according to PrimeSTAR Max amplification enzymes product description, and PCR reaction system includes:2× PrimeSTAR Max, cDNA sample, upstream and downstream primer, high purity water;Comprise the following steps that:
(1) reaction system is prepared:Each μ L of 1 μ L+ high purity waters 22 of the μ L+ primers of 2 × PrimeSTAR Max, 25 μ L+cDNA 1;
(2) PCR instrument device is put into after above-mentioned reaction system is gently mixed, following program operation is set;
(3) above-mentioned PCR primer is subjected to 1.2% agarose gel electrophoresis;
(4) observe result and reclaim target DNA fragment.
7. the construction method of overexpression ZEB2 gene plasmids according to claim 2, it is characterised in that the step (4) Middle ZEB2 PCR primer and pEGFP-C2 carriers carries out BamH I and Xba I double digestion reaction according to restriction enzyme production Product specification is carried out, and digestion system is as follows:BamH I restriction enzymes, Xba I restriction enzymes, 10 × Buffer Tango, ZEB2 PCR primer or pEGFP-C2 carriers;Comprise the following steps that:
(1) reaction system is prepared:Each 0.5 μ L+ZEB2 of μ L+BamH I and Xba I of 10 × Buffer Tango 2 PCR primer or With each 7 μ L of pEGFP-C2 carriers;
(2) above-mentioned reaction system is placed in 37 DEG C of water-baths, and acts on 4-6h;
(3) above-mentioned digestion products are subjected to 1-1.2% agarose gel electrophoresis;
(4) observe result and reclaim target DNA fragment.
8. the construction method of overexpression ZEB2 gene plasmids according to claim 2, it is characterised in that the step (4) Middle connection method is specific as follows:
(1) the μ L of dephosphorylation system 10 are prepared:CIAP1 μ l, the μ l of 10 × CIAP buffer solutions, 1 μ l, pEGFP-C2 carrier 8, to carrier Carry out dephosphorylation process;
(2) the μ L of linked system 10 are prepared:The μ l of pEGFP-C2 carriers 0.5,10 × T4DNA ligase buffer solutions after CIAP dephosphorylations The μ l of 1 μ l, T4DNA ligase, 1 μ l, PCR digestions purified product 7.5;
(3) above-mentioned reaction system is placed in 0.5ml centrifuge tube and mixed, 16 DEG C of water-baths are stayed overnight.
9. the construction method of overexpression ZEB2 gene plasmids according to claim 2, it is characterised in that the step (5) Middle connection product converts comprising the following steps that into e. coli tg1:
(1) the TG1 competent cells for being stored in 80 DEG C of ﹣ are taken out, ice bath adds 10 μ l connection products after thawing, and mixes, quiet on ice Put 30min;
(2) 42 DEG C of heat shock 90s, rapid take out puts 3min on ice;
(3) 500 μ l LB nutrient solutions, 37 DEG C, 250rpm shaken cultivations 45min are added;
(4) take out about 100 μ l conversion fluids to be applied on the LB solid mediums with corresponding resistant, 37 DEG C are inverted culture 8-12h.
10. a kind of use the application as claimed in claim 1 for being overexpressed ZEB2 gene plasmids, it is characterised in that by the mistake Expression ZEB2 gene plasmids are transfected into people's HK-2 cell lines, suppress the secretion of inflammatory factor in people's HK-2 cells.
CN201710315809.7A 2017-05-08 2017-05-08 Over-expression ZEB2 gene plasmid and construction method and application thereof Active CN107119072B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710315809.7A CN107119072B (en) 2017-05-08 2017-05-08 Over-expression ZEB2 gene plasmid and construction method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710315809.7A CN107119072B (en) 2017-05-08 2017-05-08 Over-expression ZEB2 gene plasmid and construction method and application thereof

Publications (2)

Publication Number Publication Date
CN107119072A true CN107119072A (en) 2017-09-01
CN107119072B CN107119072B (en) 2020-10-27

Family

ID=59727778

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710315809.7A Active CN107119072B (en) 2017-05-08 2017-05-08 Over-expression ZEB2 gene plasmid and construction method and application thereof

Country Status (1)

Country Link
CN (1) CN107119072B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110747229A (en) * 2019-11-22 2020-02-04 河南省医药科学研究院 Eukaryotic expression plasmid for expressing THBS4 protein, construction method and application

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008304149A1 (en) * 2007-09-28 2009-04-02 University Of Virginia Patent Foundation Benzyl-cycloalkyl sphingosine 1-phosphate receptor modulators
CN103421084A (en) * 2012-05-24 2013-12-04 上海医药工业研究院 Antibacterial compound
WO2015073531A1 (en) * 2013-11-13 2015-05-21 The Texas A & M University System Micro-rnas that modulate lymphangiogenesis and inflammatory pathways in lymphatic vessel cells
CN104998249A (en) * 2015-06-28 2015-10-28 中国人民解放军第四军医大学 SIP1 and derivative thereof in the preparation of medicine for prevention and treatment of hypertrophic scar
CN105256051A (en) * 2015-11-11 2016-01-20 首都儿科研究所 Probe set and reagent kit used for detecting pathopoiesia/susceptibility genes of congenital megacolon and relative syndromes
CN105899677A (en) * 2013-12-16 2016-08-24 博爱米拉索勒股份公司 Different levels in blood cell samples of EMT-markers for the diagnosis of cancer, in particular of colorectal (CRC) and pancreatic (PC) cancer
CN106282357A (en) * 2016-08-30 2017-01-04 武汉康圣达医学检验所有限公司 A kind of method detecting Ph like related gene position of fusion
CN106442956A (en) * 2015-08-11 2017-02-22 钱朝南 Method for screening anti-tumor metastasis compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008304149A1 (en) * 2007-09-28 2009-04-02 University Of Virginia Patent Foundation Benzyl-cycloalkyl sphingosine 1-phosphate receptor modulators
CN103421084A (en) * 2012-05-24 2013-12-04 上海医药工业研究院 Antibacterial compound
WO2015073531A1 (en) * 2013-11-13 2015-05-21 The Texas A & M University System Micro-rnas that modulate lymphangiogenesis and inflammatory pathways in lymphatic vessel cells
CN105899677A (en) * 2013-12-16 2016-08-24 博爱米拉索勒股份公司 Different levels in blood cell samples of EMT-markers for the diagnosis of cancer, in particular of colorectal (CRC) and pancreatic (PC) cancer
CN104998249A (en) * 2015-06-28 2015-10-28 中国人民解放军第四军医大学 SIP1 and derivative thereof in the preparation of medicine for prevention and treatment of hypertrophic scar
CN106442956A (en) * 2015-08-11 2017-02-22 钱朝南 Method for screening anti-tumor metastasis compounds
CN105256051A (en) * 2015-11-11 2016-01-20 首都儿科研究所 Probe set and reagent kit used for detecting pathopoiesia/susceptibility genes of congenital megacolon and relative syndromes
CN106282357A (en) * 2016-08-30 2017-01-04 武汉康圣达医学检验所有限公司 A kind of method detecting Ph like related gene position of fusion

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
F. P. SCHENA等: "MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring", 《NEPHROLOGY, DIALYSIS, TRANSPLANTATION : OFFICIAL PUBLICATION OF THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION - EUROPEAN RENAL ASSOCIATION》 *
JINYUN PU等: "Effect of Huai Qi Huang on Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells through miR-200a", 《EVIDENCE-BASED COMPLEMENTARY ANDALTERNATIVE MEDICINE》 *
NCBI: "NM_014795.3", 《GENBANK》 *
NCBI: "NP_055610.1", 《GENBANK》 *
易翔等: "ZEB2和E-CADHERIN在鼻咽癌中的表达及其临床意义", 《临床耳鼻咽喉头颈外科杂志》 *
郭靓: "炎性因子OSM诱导乳腺癌恶性演进的分子机制研究", 《中国博士学位论文全文数据库医药卫生科技辑》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110747229A (en) * 2019-11-22 2020-02-04 河南省医药科学研究院 Eukaryotic expression plasmid for expressing THBS4 protein, construction method and application

Also Published As

Publication number Publication date
CN107119072B (en) 2020-10-27

Similar Documents

Publication Publication Date Title
CN108329378A (en) Senecan paddy virus VP 1 albumen, encoding gene, hybridoma cell strain and monoclonal antibody and its application
CN110123828A (en) Application of the inhibitor of PRALR in the drug that resistance to taxol oophoroma is treated in preparation
CN110218250A (en) A kind of preparation method of grass carp component 5 polyclonal antibody
CN111139224A (en) Monoclonal cell strain resisting SWP2 protein and application thereof
CN110129318A (en) Long-chain non-coding RNA PRALR and its expression plasmid and purposes
CN110317878B (en) Long-chain non-coding RNA for diagnosis and treatment monitoring of bladder cancer and application thereof
CN107119072A (en) One kind is overexpressed ZEB2 gene plasmids and its construction method and application
CN107446949A (en) PLS3 recombinant proteins eukaryon expression plasmid and its construction method and application
CN110747199A (en) Bee stress-resistance related gene NF-Y and application thereof
CN105647970A (en) Prostate-cancer-specific PAP (prostatic acid phosphatase)-GM-CSF (granulocyte-macrophage colony-stimulating factor)-IL-6 (interluekin-6) genetic recombinant fusion protein and preparation method thereof
CN106086073A (en) A kind of expression of cytokine IL 7
CN103937871B (en) The application of SRRP35 gene and expression product in cancer diagnosis and treatment
CN103509100B (en) A kind of IL-1 R antagonist mutant
CN112961865B (en) Recombinant trastuzumab expressed by gene editing chicken bioreactor and application
CN112941020B (en) Application of chicken circular RNA in promoting proliferation of myoblasts
CN110129319A (en) A kind of siRNA of PRALR and application thereof
CN107828789A (en) Application of the inhibitor and its application and KAP1 of targeted therapy of lung cancer as drug targets in the medicine of screening anti-lung cancer
CN107868785B (en) Inhibitor for targeted therapy of lung cancer and application thereof, and application of RUVBL1 gene as drug target in screening anti-lung cancer drugs
CN104450781B (en) A kind of cell line of overexpression CIAPIN1 albumen and its preparation method and application
CN106636444A (en) Application of FAM78A gene
CN107384956A (en) Knock out application of the p53 genes in neuroglial cytoma propagation and transfer is suppressed
CN110951880A (en) Application of reagent for detecting lncRNA marker of hypopharynx cancer in preparation of product for diagnosing hypopharynx cancer
CN109706173A (en) A kind of carrier pZSW-1 reducing lung carcinoma cell multidrug resistance by RNAi silencing Egr1 gene
CN106047927A (en) Overexpression TMEM88 gene plasmid, construction method and application thereof
CN103525941A (en) Application of CTHRC1 genes in preparation of drugs for detecting/treating cervical cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant